Q-omics provides the consensus-scored CROCCP3 profile across patient tissues and cancer cell-line models. CROCCP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CROCCP3 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, CROCCP3 RNA expression shows 21,233 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LIHC, and THYM as cancer lineages where CROCCP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CROCCP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CROCCP3 survival associations across molecular data types. CROCCP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CROCCP3 RNA expression–survival associations across cancer types. High CROCCP3 expression shows unfavorable associations in ACC, KICH, LIHC and LGG, but favorable associations in HNSC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CROCCP3 RNA expression.
This table summarizes CROCCP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CROCCP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CROCCP3 shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, KIRC, CHOL and HNSC. The LIHC box plot shows higher CROCCP3 RNA expression in tumor versus normal tissue (log2 FC = +0.397, t-test p < 0.001).
This table shows molecular features associated with CROCCP3 in patient tissues and cancer cell lines. In patient samples, CROCCP3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
